Resveratrol treatment ameliorates hepatic damage via the TGF-β/SMAD signaling pathway in a phenobarbital/CCl4-induced hepatic fibrosis model

Document Type : Original Article


1 Department of Medical Biology, Faculty of Medicine, Ataturk University, Erzurum, Turkey

2 Department of Histology and Embrylogy, Faculty of Veterinary, Ataturk University, Erzurum, Turkey

3 Department of Medical Biochemistry, Faculty of Medicine, Ataturk University, Erzurum,Turkey



Objective(s): Liver fibrosis is a wound healing response characterized by excessive accumulation of extracellular matrix proteins. This study aimed to investigate the effects of resveratrol treatment on the TGF-β/SMAD signaling pathway and related biochemical parameters, apoptosis, and liver regeneration phenobarbital-CCl4 induced hepatic fibrosis rat model. 
Materials and Methods: This model was created through phenobarbital and CCl4 (0.2–0.35 ml/kg). Resveratrol (1 mg/kg/day) was administered to the fibrosis and control groups. Immunohistochemical staining was performed to evaluate αSMA, TGF-β1, and PCNA in liver tissue. The TUNEL method and Masson’s Trichome staining were used to determine apoptosis and collagen accumulation. AST, ALP, ALT, total protein, and total bilirubin levels were measured to determine biochemical status. SMAD2, SMAD3, SMAD4, and SMAD7 expression levels were measured to determine TGF-β1 related hepatic fibrosis. 
Results: The SMAD2, SMAD3, and SMAD4 mRNA expression levels were increased and the SMAD7 mRNA expression level was decreased in the fibrosis control group. The SMAD7 mRNA expression level was higher in the phenobarbital-CCl4 induced resveratrol treated group. Increased biochemical parameters indicating hepatic damage, increased number of apoptotic cells, and collagen accumulation surrounding the central vein were observed in the fibrosis group compared with the other groups. It was concluded that administration of resveratrol ameliorates the adverse effects of hepatic fibrosis by regulating biochemical parameters, controlling TGF-β1/SMAD signaling, enhancing tissue regeneration, and reducing apoptosis in liver cells. 
Conclusion: Resveratrol can be a beneficial option for the prevention of liver damage in a phenobarbital-CCl4 induced hepatic fibrosis.


Main Subjects

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209–218. 
2. Crespo Yanguas S, Cogliati B, Willebrords J, Maes M, Colle I, Van den Bossche B, et al. Experimental models of liver fibrosis. Arch Toxicol 2016; 90:1025–1048. 
3. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141:1572–1585. 
4. Xu F, Liu C, Zhou D, Zhang L. TGF-β/SMAD pathway and its regulation in hepatic fibrosis. J Histochem Cytochem 2016; 64:157–167. 
5. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol 2013; 58:593–608. 
6. Brown B, Lindberg K, Reing J, Stolz DB, Badylak SF. The basement membrane component of biologic scaffolds derived from extracellular matrix. Tissue Eng 2006; 12:519–526. 
7. Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut 1980; 21:63–71. 
8. Chatamra K, Proctor E. Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis. Br J Exp Pathol 1981; 62:283-288. 
9. Abraldes JG, Pasarín M, García-Pagán JC. Animal models of portal hypertension. World J Gastroenterol 2006; 12:6577-6584. 
10. Liu Y, Meyer C, Xu C, Weng H, Hellerbrand C, ten Dijke P, et al. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol 2013; 304:449–468. 
11. Boon MR, van der Horst G, van der Pluijm G, Tamsma JT, Smit JWA, Rensen PCN. Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev 2011; 22:221–229. 
12. Kang JS, Saunier EF, Akhurst RJ, Derynck R. The type I TGF-β receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 2008; 10:654–664. 
13. Govinden R, Bhoola KD. Genealogy, expression, and cellular function of transforming growth factor-β. Pharmacol Ther 2003; 98:257–265. 
14. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, et al. TGF-β1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol Gastrointest Liver Physiol 1999; 276:1059–1068. 
15. Dudás J, Kovalszky I, Gallai M, Nagy JO, Schaff Z, Knittel T, et al. Expression of decorin, transforming growth factor-beta1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. Am J Clin Pathol 2001; 115:725–735. 
16. Border WA, Noble NA. Evidence that TGF-β should be a therapeutic target in diabetic nephropathy. Kidney Int 1998; 54:1390–1391. 
17. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003; 12:25–29. 
18. Meng X-M, Chung ACK, Lan HY. Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci 2013; 124:243–254. 
19. Xie F, Zhang Z, Van Dam H, Zhang L, Zhou F. Regulation of TGF-β superfamily signaling by SMAD mono-ubiquitination. Cells 2014; 3:981–993. 
20. Yao Q, Xu B, Wang J, Liu H, Zhang S, Tu C. Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Complement Altern Med 2012; 12:1–11. 
21. Latella G, Vetuschi A, Sferra R, Catitti V, D’Angelo A, Zanninelli G, et al. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int 2009; 29:997–1009. 
22. Masszi A, Kapus A. Smaddening complexity: the role of Smad3 in epithelial-myofibroblast transition. Cells Tissues Organs 2010; 193:41–52. 
23. Meng XM, Huang XR, Chung ACK, Qin W, Shao X, Igarashi P, et al. Smad2 protects against TGF-β/Smad3-mediated renal fibrosis. J Am Soc Nephrol 2010; 21:1477-1487. 
24. Frémont L. Biological effects of resveratrol. Life Sci 2000; 66:663–673. 
25. Hong S-W, Jung KH, Zheng H-M, Lee H-S, Suh J-K, Park I-S, et al. The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Res 2010; 33:601–609. 
26. Godichaud S, Krisa S, Couronné B, Dubuisson L, Mérillon J, Desmoulière A, et al. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol. Hepatology 2000; 31:922–931. 
27. Bansal MB, Friedman SL. Hepatic fibrogenesis. Sherlock’s Diseases of the Liver and Biliary System 2011; 94–102. 
28. Proctor E, Chatamra K. Standardized micronodular cirrhosis in the rat. Eur Surg Res 1984; 16:182–186. 
29. Fortea JI, Fernández-Mena C, Puerto M, Ripoll C, Almagro J, Bañares J, et al. Comparison of two protocols of carbon tetrachloride-induced cirrhosis in rats–improving yield and reproducibility. Sci Rep 2018; 8:9163-9173. 
30. Hung L-M, Chen J-K, Huang S-S, Lee R-S, Su M-J. Cardioprotective effect of resveratrol, a natural anti-oxidant derived from grapes. Cardiovasc Res 2000; 47:549–555. 
31. Godichaud S, Si-Tayeb K, Augé N, Desmoulière A, Balabaud C, Payrastre B, et al. The grape-derived polyphenol resveratrol differentially affects epidermal and platelet-derived growth factor signaling in human liver myofibroblasts. Int J Biochem Cell Biol 2006; 38:629–637. 
32. Chen Y, Zheng S, Qi D, Zheng S, Guo J, Zhang S, et al. Inhibition of notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One 2012; 7:1-11. 
33. Tanriverdi G, Kaya-Dagistanli F, Ayla S, Demirci S, Eser M, Unal S, et al. Resveratrol can prevent CCl4-induced liver injury by inhibiting notch signaling pathway. Histol Histopathol 2016; 31:769-784.
34. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2008; 295:833–842. 
35. Cho S-J, Jung UJ, Choi M-S. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br J Nutr 2012; 108:2166–2175. 
36. Cheng N, Ren N, Gao H, Lei X, Zheng J, Cao W. Anti-oxidant and hepatoprotective effects of Schisandra chinensis pollen extract on CCl4-induced acute liver damage in mice. Food Chem Toxicol 2013; 55:234–240. 
37. Abdelaziz DHA, Ali SA. The protective effect of Phoenix dactylifera L. seeds against CCl4-induced hepatotoxicity in rats. J Ethnopharmacol 2014; 155:736–743. 
38. Chávez E, Reyes‐Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, et al. Resveratrol prevents fibrosis, NF‐κB activation and TGF‐β increases induced by chronic CCl4 treatment in rats. J Appl Toxicol 2008; 28:35–43. 
39. Ding J, Yu J, Wang C, Hu W, Li D, Luo Y, et al. Ginkgo biloba extract alleviates liver fibrosis induced by CCl4 in rats. Liver Int 2005; 25:1224–1232. 
40. Fan G, Tang JJ, Bhadauria M, Nirala SK, Dai F, Zhou B, et al. Resveratrol ameliorates carbon tetrachloride-induced acute liver injury in mice. Environ Toxicol Pharmacol 2009; 28:350–356. 
41. Lee E-S, Shin M-O, Yoon S, Moon J-O. Resveratrol inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Arch Pharm Res 2010; 33:925–932. 
42. Chan C, Cheng L, Lin C, Huang Y, Lin H, Lee F. The protective role of natural phytoalexin resveratrol on inflammation, fibrosis and regeneration in cholestatic liver injury. Mol Nutr Food Res 2011; 55:1841–1849. 
43. Roy S, Sannigrahi S, Majumdar S, Ghosh B, Sarkar B. Resveratrol regulates anti-oxidant status, inhibits cytokine expression and restricts apoptosis in carbon tetrachloride induced rat hepatic injury. Oxid Med Cell Longev 2011; 2011:1-12. 
44. Liu F, Sun C, Chen Y, Du F, Yang Y, Wu G. Indole-3-propionic acid-aggravated CCl4-induced liver fibrosis via the TGF-β1/Smads signaling pathway. J Clin Transl Hepatol 2021; 9:917-930. 
45. Lee TH, Kim WR, Poterucha JJ. Evaluation of elevated liver enzymes. Clin Liver Dis 2012; 16:183–198. 
46. Mohseni R, Arab Sadeghabadi Z, Goodarzi MT, Karimi J. Co-administration of resveratrol and beta-aminopropionitrile attenuates liver fibrosis development via targeting lysyl oxidase in CCl4-induced liver fibrosis in rats. Immunopharmacol Immunotoxicol 2019; 41:644–651. 
47. Cerna P, Kotyzova D, Eybl V. Protective effect of resveratrol in acute liver damage in rats. Toxicol Lett 2008; 27:45–46. 
48. Tunalı-Akbay T, Sehirli O, Ercan F, Sener G. Resveratrol protects against methotrexate-induced hepatic injury in rats. J Pharm Pharm Sci 2010; 13:303–310. 
49. Abdelsalam MM, El-Mahdy N, Abou-Saif S. Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice. Liver Res 2023; 7:71–81. 
50. Massagué J, Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000; 19:1745–1754. 
51. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad  Sci U S A 1995; 92:2572–2576. 
52. Lu P, Wang S, Cai W, Sheng J. Role of TGF-β1/Smad3 signaling pathway in secretion of type I and III collagen by vascular smooth muscle cells of rats undergoing balloon injury. J Biomed Biotechnol 2012; 2012: :965953. 
53. Bi W-R, Yang C-Q, Shi Q. Transforming growth factor-β1 induced epithelial-mesenchymal transition in hepatic fibrosis. Hepatogastroenterology 2012; 59:1960–1963. 
54. Lan HY, Chung ACK. Transforming growth factor-β and Smads. Contrib Nephrol 2011; 170:75–82. 
55. Huse M, Muir TW, Xu L, Chen Y-G, Kuriyan J, Massagué J. The TGFβ receptor activation process: An inhibitor-to substrate-binding switch. Mol Cell 2001; 8:671–682. 
56. Flanders K, Sato M, Ooshima A, Russo A, Roberts A. Smad‐3 as a mediator of the fibrotic response. Int J Exp Pathol 2004; 85:13–13. 
57. Wang W, Koka V, Lan HY. Transforming growth factor‐β and Smad signalling in kidney diseases. Nephrology 2005; 10:48–56. 
58. Li JH, Huang XR, Zhu H, Oldfield M, Cooper M, Truong LD, et al. Advanced glycation end products activate Smad signaling via TGF‐β‐dependent and‐independent mechanisms: Implications for diabetic renal and vascular disease. FASEB J 2004; 18:176–178. 
59. Li J, Campanale NV, Liang RJ, Deane JA, Bertram JF, Ricardo SD. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-β1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol 2006; 169:1527–1540. 
60. Jang CH, Kim KM, Yang JH, Cho SS, Kim SJ, Shin SM, et al. The role of lipin-1 in the regulation of fibrogenesis and TGF-β signaling in hepatic stellate cells. Toxicol Sci 2016; 153:28–38. 
61. Zhai X, Ding J, Tang Z. Resveratrol inhibits proliferation and induces apoptosis of pathological scar fibroblasts through the mechanism involving TGF-β1/Smads signaling pathway. Cell Biochem Biophys 2015; 71:1267–1272. 
62. Lee HY, Kim IK, Yoon HK, Kwon SS, Rhee CK, Lee SY. Inhibitory effects of resveratrol on airway remodeling by transforming growth factor-β/Smad signaling pathway in chronic asthma model. Allergy Asthma Immunol Res 2017; 9:25–34.